{"schema_version":"secwatch.filing_event.v1","accession":"0001628908-24-000112","form_type":"8-K","ticker":"EVH","cik":"0001628908","company_name":"Evolent Health, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.033592+00:00","generated_at":"2026-05-30T03:35:56.560586+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evolent Q3 revenue rises 21.6% to $621M, net loss $31.2M; EBITDA miss due to $42M medical cost spike","bullets":["Revenue $621.4M, up 21.6% YoY; net loss $(31.2)M vs $(33.2)M prior year.","Adjusted EBITDA $31.8M (5.1% margin), down from $48.7M (9.5%) YoY.","Medical costs exceeded expectations by $42M: $24M prior-period claims, $18M oncology spike.","Company revises 2024 Adjusted EBITDA guidance; reiterates long-term growth targets.","Record six new contracts signed, including oncology Performance Suite with top-5 payer (200k members)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628908-24-000112","json":"https://secwatch.observer/filing/0001628908-24-000112.json","markdown":"https://secwatch.observer/filing/0001628908-24-000112.md","text":"https://secwatch.observer/filing/0001628908-24-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000112/0001628908-24-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000112/evh-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:35:56.560586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}